Bristol-Myers Squibb Company · NYSE:BMY
Bristol-Myers Squibb — Chicago Multidisciplinary Symposium in Thoracic Oncology (CMSTO) 2014
34 slides from Bristol-Myers Squibb's conference presentation, Oct 31, 2014
Slide 1: CMSTO 2014 Highlights Investor Meeting
CMSTO 2014 Highlights* Investor Meeting October 31, 2014 *Chicago Multidisciplinary Symposium in Thoracic Oncology October 30 – November 1, 2014 NOT FOR PRODUCT PROMOTIONAL USE 1
Slide 2: Forward-Looking Information
Forward-Looking Information During this meeting, we will make statements about the Company’s future plans and prospects that constitute forward- looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materia
Slide 3: Today's Agenda
Today’s Agenda Immuno-Oncology Strategic Overview Developments since ASCO Lung Cancer Strategy Key Data Presented at CMSTO 2014 Upcoming Key Events Q&A CMSTO 2014 NOT FOR PRODUCT PROMOTIONAL USE 3
Slide 4: Immuno-Oncology: A Transformational Opportunity for Cancer Patients
Immuno-Oncology: A Transformational Opportunity for Cancer Patients CMSTO 2014 NOT FOR PRODUCT PROMOTIONAL USE 4
Slide 5: BMS Immuno-Oncology Vision
BMS Immuno-Oncology Vision Displace standard of care in multiple tumor types, lines of therapy and histologies – Monotherapy – Combination – Biomarker Use I-O combinations to meaningfully increase likelihood of long-term survival Expand and accelerate broad portfolio of novel mechanisms CMSTO
Slide 6: Developments Since ASCO
Developments Since ASCO CMSTO 2014 NOT FOR PRODUCT PROMOTIONAL USE 6
Slide 7: Positive Results from Phase 3 Studies
Positive Results from 2 Phase 3 Studies Checkmate -066: – Previously untreated BRAF Wild Type patients with advanced melanoma – Primary endpoint met: superior survival vs. DTIC Checkmate -037: – Advanced melanoma patients previously treated with Yervoy or BRAF inhibitor (BRAF Mutant) – Co-primar
Slide 8: Regulatory Filings for 2 Tumor Types
Regulatory Filings for 2 Tumor Types Melanoma – US: Filed advanced melanoma based on -037 • Priority Review, Breakthrough Therapy status granted by FDA • PDUFA date March 30, 2015 – EU: Filed advanced melanoma • Accelerated assessment granted by EMA Lung – EU: Filed advanced lung cancer based on
Slide 9: New Study Starts
New Study Starts Renal Cell Carcinoma – Checkmate-214: Phase 3 study of nivolumab in combination with Yervoy in 1st line Hodgkin Lymphoma – Checkmate-205: Phase 2B trial Glioblastoma – Checkmate-143: Phase 3 portion initiated CMSTO 2014 NOT FOR PRODUCT PROMOTIONAL USE 9
Slide 10: Extending Leadership through Partnerships
Extending Leadership through Partnerships Trademarks are the property of their respective owners CMSTO 2014 NOT FOR PRODUCT PROMOTIONAL USE 10
Slide 11: Lung Cancer Strategy
Lung Cancer Strategy CMSTO 2014 NOT FOR PRODUCT PROMOTIONAL USE 11
Slide 12: BMS Lung Cancer Development Strategy
BMS Lung Cancer Development Strategy Deliver the potential of I-O to the broad population – Across histologies, lines of therapy and PD-L1 status Characterize benefits of I-O with broad clinical program – Demonstrate Overall Survival – Determine role of biomarker(s) Realize the full potential
Slide 13: Lung Cancer Development Program
Lung Cancer Development Program Phase I Phase II Phase III Yervoy Tx Nivo Yervoy NSCLC Mono Tx Nivolumab NSCLC (-012) Squamous + CT (-104) Comb Tx Yervoy SCLC + CT Mono + (-156) 1st line Comb Nivolumab NSCLC PD-L1+ (-026) Nivolumab + Yervoy New Nivolumab (Planned) Combination Regimens* (>5) Nivoluma
Slide 14: Immuno-Oncology: A Transformational Opportunity for Cancer Patients
Immuno-Oncology: A Transformational Opportunity for Cancer Patients NOT FOR PRODUCT PROMOTIONAL USE 14
Slide 15: CMSTO 2014
CMSTO 2014 CMSTO 2014 NOT FOR PRODUCT PROMOTIONAL USE 15
Slide 16: CMSTO 2014 – Highlights of Key Data
CMSTO 2014 – Highlights of Key Data Study Description Key Data Presented -003 Nivo monotherapy 3-year survival rate Monotherapy ORR, Durability of Response Nivo plus platinum doublets 18-month survival rate -012 Nivo plus erlotinib 18-month survival rate Nivo plus bevacizumab Dur
Slide 17: Checkmate-012 Key Takeaways
Checkmate-012 Key Takeaways In the 1st line setting, nivolumab monotherapy or in combination provided durable responses with encouraging survival Nivolumab monotherapy was associated with a safety profile consistent with previous studies Nivolumab in combination was associated with a safety pr
Slide 18: Checkmate-003
Checkmate-003 CMSTO 2014 NOT FOR PRODUCT PROMOTIONAL USE 18
Slide 19: Checkmate-003 Overall Survival in NSCLC Patients
Checkmate-003 Overall Survival in NSCLC Patients (Up to 5 Prior Lines of Therapy) All Treated Subjects with NSCLC 1.0 0.9 Group Died/Treated Median (95% CI) 0.8 Total 99/129 9.90 (7.80, 12.40) Proportion Survival 0.7 0.6 0.5 Censored 0.4 2-year OS = 24% 0.3 0.2 3-year OS = 18% 0.1 0.0 0 3 6 9 12 15
Slide 20: Checkmate-003 OS by Nivolumab Dose in NSCLC Patients
Checkmate-003 OS by Nivolumab Dose in NSCLC Patients (Up to 5 Prior Lines of Therapy) OS rate % (95% CI) [patients at risk] Died/ 1.0 Group Treated Median (95% CI) 1-year 2-year 3-year 1 mg/kg 26/33 9.20 (5.30, 11.10) 33 (17, 49) [9] 15 (5, 30) [4] 15 (5, 30) [1] 0.9 3 mg/kg 23/37 14.90 (7.30, 30.30
Slide 21: Checkmate-003 Safety Summary
Checkmate-003 Safety Summary Treatment-Related Select AE Any Gradea,% Grade 3–4, % Category (n) (n) Patients with any treatment-related 41 (53) 5 (6) select AE Skin 16 (20) 0 Gastrointestinal 12 (15) 1 (1) Pulmonary 7 (9)b 2 (3) Endocrinopathies 6 (8) 0 Hepatic 5 (6) 1 (1) Infusion reaction 4 (5) 1
Slide 22: Checkmate-063
Checkmate-063 CMSTO 2014 NOT FOR PRODUCT PROMOTIONAL USE 22
Slide 23: Unmet Need in Refractory SQ NSCLC
Unmet Need in Refractory SQ NSCLC Massarelli1, 2003 Scartozzi2, 2010 Penrod3, 2014 Gettinger4, 2014 > 3L SQ and NSQ, 3L SQ and NSQ, 3L SQ, > 2L SQ, Population N = 43 N = 52 N = 113 N = 54 Real-world Nivolumab 1, 3 Treatment Chemo Chemo or TKI Obs Cohorta or 10 mg/kg Q2W ORR,% 2 8 – 17 Median PFS, mo
Slide 24: Checkmate-063 Study Design
Checkmate-063 -063 Study Design Phase II Nivolumab in Advanced, 3rd Line + Squamous Cell Lung Cancer Endpoints Primary: • Confirmed overall response • Stage IIIB/IV Nivolumab 3 mg/kg rate (IRC assessed) SQ NSCLC IV Q2W Secondary: • Confirmed overall response • ≥2 lines of Treat until rate (investiga
Slide 25: Checkmate-063 Baseline Demographics
Checkmate-063 Baseline Demographics Nivolumab 3 mg/kg N = 117 Median age, years (range) 65 (37–87) ECOG PS, % 0 22 1 78 Gender, % Male 73 Number of prior systemic regimens, % 2 35 ≥3 65 Best response to most recent prior regimen, % CR or PR 4 SD 27 PD 61 Time from completion of most recent prior reg
Slide 26: Clinical Activity of Nivolumab
Checkmate-063 Clinical Activity of Nivolumab IRC Assessed (per RECIST 1.1)a ORR, % (n) 15 (17) [95% CI] [9, 22] Disease control rate, % (n) 40 (47) Median DOR, months (range) NR (2+, 12+) Ongoing responders, % (n) 76 (13) Median time to response, months (range) 3 (2, 9) Median PFS, months (95% CI) 2
Slide 27: Best Reduction from Baseline
Checkmate-063 Response and Survival Status By Best Reduction in Target Lesion (IRC Assessed)a 100 75 Alive Best Reduction from Baseline Deceased 50 in Target Lesion (%) Confirmed responders 25 0 -25 -50 Patient n = 95 response-evaluable -75 -100 aBased on July 2014 DBL; 22/117 treated patients are n
Slide 28: Overall Survival: All Treated Patients
Checkmate-063 Overall Survival: All Treated Patientsa 1.0 Median OS, months (95% CI) 8.2 (6.1, 11) 0.9 1-year OS rate, % (95% CI) 41 (32, 50) Probability of Survival 0.8 Number of events 72/117 0.7 0.6 Median OS = 8.2 months 0.5 1-year OS = 41% 0.4 0.3 0.2 0.1 0.0 0 3 6 9 12 15 18 Number of Patients
Slide 29: ORR by PD-L1 Expression (IRC Assessed)
Checkmate-063 ORR by PD-L1 Expression (IRC Assessed) a 76 evaluable samples Subgroups ORR, % (n/N) Overall 15 (17/117) >1% 20 (9/45) <1% 13 (4/31) PD-L1 >5% 24 (6/25) <5% 14 (7/51) Indeterminate/NEb 30 (3/10) a Based on a July 2014 DBL b No quantifiable PD-L1 expression NE = not evaluable CMSTO 20
Slide 30: Nivolumab Safety Summary
Checkmate-063 Nivolumab Safety Summary* Nivolumab 3 mg/kg (N = 117) Category Any Grade Grade 3–4 Total patients with an event, % 74 17 Fatigue 33 4 Decreased appetite 19 0 Asthenia 12 0 Rash 11 1 Nausea 15 0 Diarrhea 10 3 * Of the adverse events included in the table, no events were grade 5 Grade
Slide 31: Checkmate-063 Key Takeaways
Checkmate-063 Key Takeaways Highly refractory patient population with no treatment alternatives – 65% had already failed 3+ lines – 61% with progressive disease as best response to most recent prior therapy Clinically meaningful and durable efficacy – 1 yr OS of 41% and ORR of 15% per RECIST 1.1
Slide 32: Key Upcoming Nivolumab Events
Key Upcoming Nivolumab Events Data Presentations: Checkmate -066: Phase 3 vs. DTIC in 1st Line Melanoma (SMR Nov 13-16) Checkmate -039: Phase I in Hematologic Malignancies (ASH Dec 6-9) Regulatory Filings: Checkmate -063: completion of rolling submission by year end New Study Starts: Phase 3
Slide 33: Immuno-Oncology: A Transformational Opportunity for Cancer Patients
Immuno-Oncology: A Transformational Opportunity for Cancer Patients CMSTO 2014 NOT FOR PRODUCT PROMOTIONAL USE 33
Slide 34: CMSTO 2014 Highlights Investor Meeting
CMSTO 2014 Highlights* Investor Meeting October 31, 2014 *Chicago Multidisciplinary Symposium in Thoracic Oncology October 30 – November 1, 2014 NOT FOR PRODUCT PROMOTIONAL USE 34